Square Pharmaceuticals PlcDSEBD: SQURPHARMA

SQURPHARMA: Net profit rose 13% year-over-year, with EPS at Tk. 14.32 and strong asset growth

· Issued by Square Pharmaceuticals Plc

Consolidated revenue and net profit grew 6% and 13% year-over-year, with EPS up to Tk. 14.32. Cash flow per share declined due to absence of prior year one-offs, while NAV per share rose to Tk. 145.52.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Square Pharmaceuticals

All Square Pharmaceuticals news releases